Wegovy vs Mounjaro side effects, compared honestly

You've weighed up both pens and want to know which will upset your stomach more

This is the honest starting point most people arrive at. You've read that both Wegovy and Mounjaro cause nausea, and you want to know whether one is gentler than the other before you commit. The straight answer is that they cause the same kinds of effects, because both slow how quickly your stomach empties and dial down appetite signalling.

Mounjaro (tirzepatide) acts on two gut-hormone receptors, GIP and GLP-1. Wegovy (semaglutide) acts on one, the GLP-1 receptor. That extra pathway is part of why tirzepatide tends to produce more weight loss on average, but it does not automatically mean rougher side effects. In practice the intensity of nausea or diarrhoea depends far more on your dose, how fast it's increased and how your own body responds than on which brand is in the pen.

The NHS guidance on tirzepatide and the equivalent page on semaglutide list overlapping symptoms: nausea, being sick, loose stools or constipation, indigestion, wind, tiredness and headache. A useful way to think about it is that the side-effect menu is nearly identical; the portions differ from person to person. If you want the two set out side by side, our page on tirzepatide versus semaglutide side effects unpacks it by ingredient rather than brand. That's worth a look.

What the symptom lists share, and where they diverge

Start with what overlaps, because that's most of it. On either medicine you might notice queasiness, occasional vomiting, changes in bowel habit in either direction, reflux, burping, low energy and mild headaches. Injection-site reactions, a bit of redness or itching where the needle went, happen with both. These are the effects our prescribers hear about most weeks, and the pattern is reassuringly predictable: they cluster around the first few weeks and around each step up in dose, then tend to ease.

Where things diverge is subtler. Because tirzepatide is a dual agonist and reaches higher relative potency at its top strengths, some people report the appetite suppression feeling stronger, which can tip into skipping meals and feeling wiped out if you're not careful with protein and fluids. Semaglutide's single pathway is very well characterised across large trials, so its profile is arguably the more predictable of the two. Neither of those is a clean scoreboard, though.

If you're trying to work out which lands lighter for you, our comparisons on whether Mounjaro or Wegovy causes fewer side effects and on which tends to bring more lay out the nuance without pretending there's a universal answer. There isn't one. The medicine that suits your neighbour may not suit you, which is exactly why an assessment matters more than a league table.

Reading the numbers without being misled by them

Trial data can look like a clear verdict when it isn't. In the head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction over 72 weeks than semaglutide 2.4mg in adults with obesity and no diabetes. That's a real difference in effectiveness. It does not translate into a matching gap in how badly people tolerate each drug, because the trials weren't designed to rank discomfort.

Both carry the Black Triangle symbol, meaning the MHRA is still collecting extra safety data on them, which is normal for newer medicines and not a red flag. The higher-strength Wegovy 7.2mg dose, approved by the MHRA in 2026, narrows the effectiveness gap considerably, so the picture keeps shifting. For the fuller effectiveness-and-safety view rather than just symptoms, our Mounjaro versus Wegovy safety page is the better home. Treat trial percentages as context, not a personal forecast.

The serious but uncommon risks that apply to both

Most side effects are mild and pass. A smaller number are serious and worth knowing by name. In January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis as an infrequent but potentially serious effect across GLP-1 medicines. The signal to act on is severe, persistent stomach pain that may spread through to your back, with or without being sick. If that happens, seek urgent medical help.

Other rarer concerns shared by both medicines include gallbladder problems, dehydration or kidney strain following a bad bout of vomiting or diarrhoea, and allergic reactions. Because these apply whichever brand you're on, the safety conversation isn't really a Wegovy-versus-Mounjaro one at all. It's a GLP-1 conversation, and it belongs with your prescriber and the patient information leaflet that comes in the box.

You can report any suspected side effect through the MHRA's Yellow Card scheme, which also helps flag suspect sellers. We'd always rather you told us and the Yellow Card scheme early than sat on something that worried you. If you're weighing up whether one drug feels harder to tolerate day to day, the honest deep-dive on whether side effects are worse on Mounjaro or Wegovy keeps the rare risks in proportion alongside the everyday ones.

Why your starting dose changes everything about tolerability

Here's the part comparisons often skip. Neither medicine starts you at its full strength. Mounjaro begins at 2.5mg and Wegovy at 0.25mg, and those opening doses exist to let your system settle rather than to drive weight loss. The first pen's real job is adjustment. Increases then happen gradually, roughly every four weeks, decided by your prescriber based on how you're getting on.

This matters enormously when people compare notes. Someone struggling on Mounjaro might simply be higher up the dose ladder than a friend on Wegovy, so a brand-versus-brand grumble is often really a dose-versus-dose one. Slowing a titration, or holding at a tolerable step for longer, tends to calm the gut symptoms that make people want to quit. That's a clinical judgement, not something to freelance at home.

Eating pattern helps too: smaller portions, enough protein, staying hydrated and easing off very fatty or spicy food while your body adapts. None of that is a prescription from us, just the practical stuff our prescribers talk through. If you're specifically curious whether Wegovy tends to land more gently because its steps start lower, our page on whether Wegovy has fewer side effects than Mounjaro looks at exactly that dose-ladder effect. The takeaway is simple: judge tolerability at a matched dose, or you're comparing two different things.

Ozempic isn't part of this comparison, and here's why

People often fold Ozempic into a Wegovy-versus-Mounjaro discussion, so it's worth being clear. Ozempic is also semaglutide, the same active ingredient as Wegovy, but in the UK it is licensed for type 2 diabetes, not weight loss. Rybelsus, the oral form of semaglutide, is likewise a type 2 diabetes medicine, not a weight-management one. That licensing distinction genuinely matters and isn't just paperwork.

It means that when you read side-effect chatter about "Ozempic", you're reading about semaglutide used for a different purpose and often at different doses from Wegovy. The symptom profile is similar because the molecule is the same, but the right weight-loss comparison is Wegovy against Mounjaro, not Ozempic against Mounjaro. If your reading has pulled Ozempic into the mix, our page on Ozempic versus Mounjaro side effects explains the overlap and the licensing line clearly.

None of these medicines is suitable for everyone. They're not recommended in pregnancy, when breastfeeding, or if you're trying to conceive, and they aren't licensed for under-18s. A history of pancreatitis, certain thyroid cancers or particular gut conditions needs discussing before either is considered. Those are conversations, not tick-boxes, which is why we run a proper assessment rather than a form-filling exercise.

How switching between them affects what you feel

Some people move from one to the other, often when a dose plateaus or a medicine doesn't agree with them, and they want to know whether the side effects reset. Broadly, yes: switching usually means re-establishing tolerance, because the new medicine has its own starting dose and its own titration. Jumping straight to an equivalent high strength isn't how it works, and doing so would risk a rough few weeks.

A prescriber decides the right entry point when you change, taking account of where you'd reached on the first medicine and how you tolerated it. That's genuinely individual. There's no fixed conversion you should apply yourself, and the patient information leaflet is your reference for the specifics. Our page on side effects when switching from Mounjaro to Wegovy walks through what to expect, and whether that switch is safe answers the question people ask most before they make the change.

Whichever way you're leaning, the decision about which medicine, at which dose, and whether to switch, is a clinical one our prescribers make with you, not a verdict to reach from a comparison table. You can check your eligibility with us in a free consultation, reviewed the same day by a real clinician who reads your answers properly. If you'd like the wider picture first, our Wegovy versus Mounjaro overview and the price comparison cover the ground beyond symptoms.

Related questions we've answered

• Wegovy or Mounjaro: which has fewer side effects?
• Wegovy side effects compared to Mounjaro
• Tirzepatide vs Ozempic side effects
• Mounjaro and Wegovy side effects together
• About nume and our GPhC-registered pharmacy